Digiqole ad

Multiple sclerosis drug helps coronavirus patients recover, Phase 2 trial suggests

 Multiple sclerosis drug helps coronavirus patients recover, Phase 2 trial suggests

A drug commonly prescribed to treat multiple sclerosis helped reduce the risk of severe disease from Covid-19, British researchers reported Thursday. But more research is needed to show whether the drug, which calms down the immune system, can help people with severe coronavirus infections.

“SNG001 reduced the odds of developing severe disease or dying by 79%,” the researchers wrote in the journal The Lancet Respiratory Medicine. SNG001 is an inhaled formula of interferon beta-1a, typically used to decrease inflammation and reduce the nerve damage caused by multiple sclerosis. In the trial, SNG001 was administered to 48 patients using a nebulizer, while 50 patients received the placebo.

After two weeks, patients who got the daily treatment were twice as likely to get better by day 15 or 16 and more than three times as likely to improve by day 28 than those who got the placebo, the researchers found. However, “there was no significant difference between treatment groups in the odds of hospital discharge or time to hospital discharge,” the researchers wrote.

From Synairgen and other institutions, the researchers found that during the two weeks of treatment, 21 patients — or 44% — in the SNG001 group recovered from the disease compared with 11 patients — or 22% — in the placebo group. By the 28th day, 58% in the SNG001 group had recovered compared with 35% in the placebo group. Overall, three patients died during the study, and all were in the placebo group.

The researchers also found that 11 patients — or 22% — in the placebo group developed severe disease by day 16 compared with six patients — or 13% — in the SNG001 group.
The most common adverse event in the SNG001 group was headache.

“SNG001, a treatment already studied and shown to be well tolerated in patients with asthma and COPD, seems also to be well tolerated in patients admitted to hospital with COVID-19,” the researchers wrote in the study. “These encouraging data provide a strong rationale for larger, international studies in the context of the ongoing clinical burden of COVID-19.” The study comes with limitations, including that the number of patients in the study was small.

There would need to be a Phase 3 trial.’

“There seems to be possibly a signal here, but it’s unclear how much of a signal. There’s no evidence that it’s a dramatic signal, like a mortality signal necessarily, and it’s a small study. I think the authors of the paper sum it up best when they say there would need to be a Phase 3 trial,” said Dr. Jay Finigan, pulmonologist and director of The Respiratory Centers of Excellence at National Jewish Health in Denver, who was not involved in the new study.

Currently, the drug remdesivir is the only treatment approved by the US Food and Drug Administration for Covid-19. Some other therapies — Eli Lilly’s antibody treatment and convalescent plasma — have received emergency use authorizations for the treatment of Covid-19. Additionally, several experimental treatments are currently being studied.

“There are certainly lots of different drugs with different delivery mechanisms. There are other inhaled drugs that are being thought about and looked at and they target different areas,” Finigan said.

“There are antiviral drugs, there are drugs acting on the immune system, antibodies, there are drugs that are trying to target inflammation and some of the inflammatory mediators,” he said. “All in all, unfortunately, the data that have come out in this population of patients have been pretty largely consistent in that none of them have shown a mortality benefit with the exception of dexamethasone,” a corticosteroid. 

When it comes to SNG001, “larger randomized clinical trials” are needed, Nathan Peiffer-Smadja and Yazdan Yazdanpanah, both of Bichat-Claude Bernard Hospital in Paris, wrote in an editorial that published alongside the new study in The Lancet Respiratory Medicine.

“The safety of nebulized interferon beta-1a will be of special interest since nebulization of interferon has no marketing authorization for any indication yet,” Peiffer-Smadja and Yazdanpanah wrote.

“It will also be worthwhile to investigate whether interferon beta-1a has an impact on prolonged symptoms of COVID-19, especially pulmonary symptoms,” they wrote. “To optimize the antiviral effect of interferon beta, there is a greater rationale to target patients at an early stage of the disease.”

Source: https://edition.cnn.com/

Digiqole ad

Related post

Leave a Reply

Your email address will not be published. Required fields are marked *